« Previous
Next »
Titles
- Abuse-deterrent formulations of opioids: effectiveness and value : final evidence report1
- Anabolic therapies for osteoporosis in postmenopausal women: effectiveness and value : final evidence report1
- Cognitive and mind-body therapies for chronic low back and neck pain: effectiveness and value : final evidence report1
- Controversies in obesity management: a technology assessment : final report1
- Controversies in the management of patients with type 2 diabetes: final report1
- Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report1
- Management of patients with opioid dependence: a review of clinical, delivery system, and policy options1
- Obeticholic acid for the treatment of nonalcoholic steatohepatitis: comparative clinical effectiveness and value : evidence report1
- Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report1
- Palliative care in the outpatient setting: a comparative effectiveness report : final report1
- Poly ADP-ribose polymerase (PARP) inhibitors for ovarian cancer: effectiveness and value : final evidence report1
- Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report1
- Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report1
- The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report1
- The path to a high performance U.S. health system: a 2020 vision and the policies to pave the way1
- Using comparative effectiveness research to pay equally for equivalent outcomes: an evaluation of a multi-stakeholder effort focused on prostate cancer treatments1
- Value proposition: the role of cost-effectiveness in coverage decisions1
- Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia: effectiveness and value : final evidence report1
- What California stands to gain: the impact of the stimulus package on health care1
- Why health plans should go to the "MAT" in the fight against opioid addiction1